Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A tumor specific single chain antibody dependent gene expression system

M N Mary1, C Venot, C Caron de Fromentel

  • 1Gene Medicine Department, Rhône-Poulenc Rorer S.A., Vitry-sur-Seine, France.

Oncogene
|February 2, 1999
PubMed
Summary

Researchers created a novel gene therapy tool called trabodies. These synthetic transcription factors target mutant p53 in tumor cells, enabling specific gene expression for targeted therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The first French fall prevention day for elderly people].

Geriatrie et psychologie neuropsychiatrie du vieillissement·2025
Same author

Structural and functional brain imaging after treatment with selective-serotonin reuptake-inhibitors in obsessive-compulsive disorder: A mini review.

Journal of affective disorders·2023
Same author

Imaging associations of self-injurious behaviours amongst patients with Borderline Personality Disorder: A mini-review.

Journal of affective disorders·2021
Same author

PER2 C111G polymorphism, cognitive reserve and cognition in subjective cognitive decline and mild cognitive impairment: a 10-year follow-up study.

European journal of neurology·2020
Same author

Assessing the effectiveness of subjective cognitive decline plus criteria in predicting the progression to Alzheimer's disease: an 11-year follow-up study.

European journal of neurology·2020
Same author

Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.

Oncogene·2017

Area of Science:

  • Molecular Biology
  • Gene Therapy
  • Immunology

Background:

  • Conditional gene expression systems are crucial for targeted gene therapy.
  • Developing systems that target specific pathological molecules is a key challenge.
  • Existing methods lack specificity for certain cellular or tissue types.

Purpose of the Study:

  • To engineer a synthetic transcription factor for conditional gene expression.
  • To create a system that specifically targets tumor cells with mutant p53.
  • To develop a novel class of transcription-activating antibodies ('trabodies').

Main Methods:

  • Fused a single-chain variable fragment (scFv) antibody targeting p53 with a tetracycline repressor DNA-binding domain.
  • Constructed a synthetic promoter with tetracycline-operator sequences.

Related Experiment Videos

  • Tested the system's ability to induce gene expression in cell lines with mutant p53, wild-type p53, and non-transformed cells.

    • Main Results:

    • The synthetic transcription factor specifically bound to mutant p53.
    • Gene expression was successfully achieved in tumor cells harboring endogenous mutant p53.
    • No significant gene expression was observed in wild-type p53 tumor cells or non-transformed cells.
    • Demonstrated intracellular expression and scFv-mediated specific gene induction.

    Conclusions:

    • A novel class of transcriptional transactivators, termed 'trabodies', has been developed.
    • Trabodies enable targeted gene expression in specific cell types based on disease-related protein expression.
    • This technology holds potential for various therapeutic applications where specific antibody targeting is desired.